Literature DB >> 23382369

Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?

Michele A Scully1, Valerie A Cwik, Bruce C Marshall, Emma Ciafaloni, Jodi M Wolff, Thomas S Getchius, Robert C Griggs.   

Abstract

OBJECTIVE: To review current approaches for obtaining patient data in Duchenne muscular dystrophy (DMD) and consider how monitoring and comparing outcome measures across DMD clinics could facilitate standardized and improved patient care.
METHODS: We reviewed annual standardized data from cystic fibrosis (CF) clinics and DMD care guidelines and consensus statements; compared current approaches to obtain DMD patient data and outcome measures; and considered the best method for implementing public reporting of outcomes, to drive improvements in health care delivery.
RESULTS: Current methods to monitor DMD patient information (MD STARnet, DuchenneConnect, and TREAT-NMD) do not yet provide patients with comparative outcome data. The CF patient registry allows for reporting of standard outcomes across clinics and is associated with improved CF outcomes. A similar patient registry is under development for the Muscular Dystrophy Association (MDA) clinic network. Suggested metrics for quality care include molecular diagnosis, ambulatory status and age at loss of ambulation, age requiring ventilator support, and survival.
CONCLUSIONS: CF longevity has increased by almost 33% from 1986 to 2010, in part due to a CF patient registry that has been stratified by individual care centers since 1999, and publically available since 2006. Implementation of outcome reporting for MDA clinics might promote a similar benefit to patients with DMD.

Entities:  

Mesh:

Year:  2013        PMID: 23382369      PMCID: PMC3589293          DOI: 10.1212/WNL.0b013e318282334e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  The case for a global rare-diseases registry.

Authors:  Christopher B Forrest; Ronald J Bartek; Yaffa Rubinstein; Stephen C Groft
Journal:  Lancet       Date:  2010-07-30       Impact factor: 79.321

2.  A story of success: continuous quality improvement in cystic fibrosis care in the USA.

Authors:  Bradley S Quon; Christopher H Goss
Journal:  Thorax       Date:  2011-08-03       Impact factor: 9.139

3.  Collaborating to bring new therapies to the patient--the TREAT-NMD model.

Authors:  K Bushby; S Lynn; T Straub
Journal:  Acta Myol       Date:  2009-07

4.  Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy.

Authors:  Dennis J Matthews; Katherine A James; Lisa A Miller; Shree Pandya; Kimberly A Campbell; Emma Ciafaloni; Katherine D Mathews; Timothy M Miller; Christopher Cunniff; F John Meaney; Charlotte M Druschel; Paul A Romitti; Deborah J Fox
Journal:  J Child Neurol       Date:  2010-03-05       Impact factor: 1.987

5.  The muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology.

Authors:  Lisa A Miller; Paul A Romitti; Christopher Cunniff; Charlotte Druschel; Katherine D Mathews; F John Meaney; Dennis Matthews; Jiji Kantamneni; Zhen-Fang Feng; Nancy Zemblidge; Timothy M Miller; Jennifer Andrews; Deborah Fox; Emma Ciafaloni; Shree Pandya; April Montgomery; Aileen Kenneson
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2006-11

6.  Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  R T Moxley; S Ashwal; S Pandya; A Connolly; J Florence; K Mathews; L Baumbach; C McDonald; M Sussman; C Wade
Journal:  Neurology       Date:  2005-01-11       Impact factor: 9.910

7.  Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-10-16       Impact factor: 17.586

Review 8.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

9.  Long-term benefit from prednisone therapy in Duchenne muscular dystrophy.

Authors:  G M Fenichel; J M Florence; A Pestronk; J R Mendell; R T Moxley; R C Griggs; M H Brooke; J P Miller; J Robison; W King
Journal:  Neurology       Date:  1991-12       Impact factor: 9.910

Review 10.  Glucocorticoid corticosteroids for Duchenne muscular dystrophy.

Authors:  A Y Manzur; T Kuntzer; M Pike; A Swan
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23
View more
  10 in total

Review 1.  What can Duchenne Connect teach us about treating Duchenne muscular dystrophy?

Authors:  Richard T Wang; Stanley F Nelson
Journal:  Curr Opin Neurol       Date:  2015-10       Impact factor: 5.710

2.  Dystrophin hydrophobic regions in the pathogenesis of Duchenne and Becker muscular dystrophies.

Authors:  Yingyin Liang; Songlin Chen; Jianzong Zhu; Xiangxue Zhou; Chen Yang; Lu Yao; Cheng Zhang
Journal:  Bosn J Basic Med Sci       Date:  2015-05-20       Impact factor: 3.363

3.  Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy.

Authors:  Elizabeth M McNally; Jonathan R Kaltman; D Woodrow Benson; Charles E Canter; Linda H Cripe; Dongsheng Duan; Jonathan D Finder; William J Groh; Eric P Hoffman; Daniel P Judge; Naomi Kertesz; Kathi Kinnett; Roxanne Kirsch; Joseph M Metzger; Gail D Pearson; Jill A Rafael-Fortney; Subha V Raman; Christopher F Spurney; Shari L Targum; Kathryn R Wagner; Larry W Markham
Journal:  Circulation       Date:  2015-05-05       Impact factor: 29.690

4.  Clinical Follow-Up for Duchenne Muscular Dystrophy Newborn Screening: A Proposal.

Authors:  Jennifer M Kwon; Hoda Z Abdel-Hamid; Samiah A Al-Zaidy; Jerry R Mendell; Annie Kennedy; Kathi Kinnett; Valerie A Cwik; Natalie Street; Julie Bolen; John W Day; Anne M Connolly
Journal:  Muscle Nerve       Date:  2016-06-13       Impact factor: 3.217

Review 5.  Newborn screening for Duchenne muscular dystrophy in China: follow-up diagnosis and subsequent treatment.

Authors:  Qing Ke; Zheng-Yan Zhao; Robert Griggs; Veronica Wiley; Anne Connolly; Jennifer Kwon; Ming Qi; Daniel Sheehan; Emma Ciafaloni; R Rodney Howell; Petra Furu; Peter Sazani; Arvind Narayana; Michele Gatheridge
Journal:  World J Pediatr       Date:  2017-05-17       Impact factor: 2.764

6.  Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.

Authors:  Michela Guglieri; Kate Bushby; Michael P McDermott; Kimberly A Hart; Rabi Tawil; William B Martens; Barbara E Herr; Elaine McColl; Jennifer Wilkinson; Janbernd Kirschner; Wendy M King; Michele Eagle; Mary W Brown; Tracey Willis; Deborah Hirtz; Perry B Shieh; Volker Straub; Anne-Marie Childs; Emma Ciafaloni; Russell J Butterfield; Iain Horrocks; Stefan Spinty; Kevin M Flanigan; Nancy L Kuntz; Giovanni Baranello; Helen Roper; Leslie Morrison; Jean K Mah; Adnan Y Manzur; Craig M McDonald; Ulrike Schara; Maja von der Hagen; Richard J Barohn; Craig Campbell; Basil T Darras; Richard S Finkel; Giuseppe Vita; Imelda Hughes; Tiziana Mongini; Elena Pegoraro; Matthew Wicklund; Ekkehard Wilichowski; W Bryan Burnette; James F Howard; Hugh J McMillan; Mathula Thangarajh; Robert C Griggs
Journal:  Contemp Clin Trials       Date:  2017-04-24       Impact factor: 2.226

Review 7.  Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.

Authors:  Lisa G Rider; Katalin Dankó; Frederick W Miller
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

8.  Current management of Duchenne muscular dystrophy in the Middle East: expert report.

Authors:  Mohammed Al Jumah; Mohammad Al Muhaizea; Ahmed Al Rumayyan; Abdulaziz Al Saman; Ali Al Shehri; Edward Cupler; Mohammed Jan; Abubaker Al Madani; Waseem Fathalla; Pawan Kashyape; Gururaj Kodavooru; Khalid Al Thihli; Laila Bastaki; Andre Megarbane; Cristina Skrypnyk; Gholamreza Zamani; Sylvie Tuffery-Giraud; Andoni Urtizberea; Carlos Ignacio Ortez González
Journal:  Neurodegener Dis Manag       Date:  2019-06-05

9.  China's shift from population control to population quality: Implications for neurology.

Authors:  Qing Ke; Li Zhang; Chaying He; Zhengyan Zhao; Ming Qi; Robert C Griggs; Michele A Gatheridge
Journal:  Neurology       Date:  2016-08-23       Impact factor: 9.910

10.  The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases.

Authors:  Sunil Rodger; Hanns Lochmüller; Adrian Tassoni; Kathrin Gramsch; Kirsten König; Kate Bushby; Volker Straub; Rudolf Korinthenberg; Janbernd Kirschner
Journal:  Orphanet J Rare Dis       Date:  2013-10-23       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.